Q3 2020 Eli Lilly and Co Earnings Call Transcript
Ladies and gentlemen, thank you for standing by, and welcome to Lilly's Q3 2020 Earnings Call. (Operator Instructions) And as a reminder, your conference is being recorded.
I would now like to turn the conference over to your host, Mr. Kevin Hern. Please go ahead.
Good morning. Thank you for joining us for Eli Lilly and Company's Q3 2020 Earnings Call. I'm Kevin Hern, Vice President of Investor Relations. Joining me on today's call are Dave Ricks, Lilly's Chairman and CEO; Josh Smiley, Chief Financial Officer; Dr. Dan Skovronsky, Chief Scientific Officer; Anne White, President of Lilly Oncology; Patrik Jonsson, President of Lilly USA; Mike Mason, President of Lilly Diabetes; and Ilya Yuffa, President of Lilly Bio-Medicines. We're also joined by Sara Smith and Mike Czapar of the Investor Relations team.
During this conference call, we anticipate making projections and forward-looking statements based on our current expectations. Our actual results could differ materially due to a number of factors,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |